Identification
- Summary
Lysine is an amino acid commonly found as a component of total parenteral nutrition.
- Brand Names
- Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %
- Generic Name
- Lysine
- DrugBank Accession Number
- DB00123
- Background
Lysine (abbreviated as Lys or K) is an α-amino acid with the chemical formula HO2CCH(NH2)(CH2)4NH2. This amino acid is an essential amino acid, which means that humans cannot synthesize it. Its codons are AAA and AAG. Lysine is a base, as are arginine and histidine. The ε-amino group acts as a site for hydrogen binding and a general base in catalysis. Common posttranslational modifications include methylation of the ε-amino group, giving methyl-, dimethyl-, and trimethyllysine. The latter occurs in calmodulin. Other posttranslational modifications include acetylation. Collagen contains hydroxylysine which is derived from lysine by lysyl hydroxylase. O-Glycosylation of lysine residues in the endoplasmic reticulum or Golgi apparatus is used to mark certain proteins for secretion from the cell.
- Type
- Small Molecule
- Groups
- Approved, Nutraceutical
- Structure
Structure for Lysine (DB00123)
- Weight
- Average: 146.1876
Monoisotopic: 146.105527702 - Chemical Formula
- C6H14N2O2
- Synonyms
- (S)-2,6-diaminohexanoic acid
- (S)-lysine
- (S)-α,ε-diaminocaproic acid
- 6-ammonio-L-norleucine
- L-2,6-Diaminocaproic acid
- L-lys
- L-Lysin
- L-Lysine
- LYS
- Lysina
- Lysine
- Lysine acid
- Lysinum
Pharmacology
- Indication
Supplemental lysine has putative anti-herpes simplex virus activity. There is preliminary research suggesting that it may have some anti-osteoporotic activity.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Weight loss Combination Product in combination with: Cyproheptadine (DB00434) •••••••••••• •••••• •••••• Used in combination to treat Weight loss Combination Product in combination with: Cyproheptadine (DB00434) •••••••••••• •••••• •••••• Used in combination to treat Weight loss Combination Product in combination with: Cyproheptadine (DB00434) •••••••••••• •••••• •••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Insures the adequate absorption of calcium; helps form collagen ( which makes up bone cartilage & connective tissues); aids in the production of antibodies, hormones & enzymes. Recent studies have shown that Lysine may be effective against herpes by improving the balance of nutrients that reduce viral growth. A deficiency may result in tiredness, inability to concentrate, irritability, bloodshot eyes, retarded growth, hair loss, anemia & reproductive problems.
- Mechanism of action
Proteins of the herpes simplex virus are rich in L-arginine, and tissue culture studies indicate an enhancing effect on viral replication when the amino acid ratio of L-arginine to lysine is high in the tissue culture media. When the ratio of L-lysine to L-arginine is high, viral replication and the cytopathogenicity of herpes simplex virus have been found to be inhibited. L-lysine may facilitate the absorption of calcium from the small intestine.
Target Actions Organism UHigh affinity cationic amino acid transporter 1 Not Available Humans UCationic amino acid transporter 4 Not Available Humans UCationic amino acid transporter 3 Not Available Humans ULow affinity cationic amino acid transporter 2 Not Available Humans ULysine--tRNA ligase Not Available Humans - Absorption
Absorbed from the lumen of the small intestine into the enterocytes by an active transport process
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Hepatic
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category Biotin Metabolism Metabolic 2-Aminoadipic 2-Oxoadipic Aciduria Disease Lysine Degradation Metabolic Hyperlysinemia II or Saccharopinuria Disease Multiple Carboxylase Deficiency, Neonatal or Early Onset Form Disease Pyridoxine Dependency with Seizures Disease Biotinidase Deficiency Disease Glutaric Aciduria Type I Disease Saccharopinuria/Hyperlysinemia II Disease Carnitine Synthesis Metabolic Hyperlysinemia I, Familial Disease - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Lysine acetate TTL6G7LIWZ 57282-49-2 RRNJROHIFSLGRA-JEDNCBNOSA-N Lysine dihydrate Not Available Not Available Not applicable Lysine hydrochloride JNJ23Q2COM 657-27-2 BVHLGVCQOALMSV-JEDNCBNOSA-N Lysine monohydrate F7625B974U 39665-12-8 HZRUTVAFDWTKGD-JEDNCBNOSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Lysine hydrochloride (145 mg / 100 mL) + Alanine (520 mg / 100 mL) + Arginine (290 mg / 100 mL) + Dextrose, unspecified form (10 g / 100 mL) + Dipotassium phosphate (130.5 mg / 100 mL) + Glycine (260 mg / 100 mL) + Histidine (120 mg / 100 mL) + Isoleucine (150 mg / 100 mL) + Leucine (182.5 mg / 100 mL) + Magnesium chloride (25.5 mg / 100 mL) + Methionine (100 mg / 100 mL) + Phenylalanine (140 mg / 100 mL) + Proline (170 mg / 100 mL) + Serine (125 mg / 100 mL) + Sodium acetate (170 mg / 100 mL) + Sodium chloride (29.3 mg / 100 mL) + Threonine (105 mg / 100 mL) + Tryptophan (45 mg / 100 mL) + Tyrosine (10 mg / 100 mL) + Valine (145 mg / 100 mL) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2015-08-05 Canada 
2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Clinimix Lysine hydrochloride (145 mg / 100 mL) + Alanine (520 mg / 100 mL) + Arginine (260 mg / 100 mL) + Dextrose, unspecified form (10 g / 100 mL) + Dipotassium phosphate (130.5 mg / 100 mL) + Glycine (520 mg / 100 mL) + Histidine (110 mg / 100 mL) + Isoleucine (120 mg / 100 mL) + L-Leucine hydrochloride (155 mg / 100 mL) + Magnesium chloride (25.5 mg / 100 mL) + Methionine (145 mg / 100 mL) + Phenylalanine hydrochloride (155 mg / 100 mL) + Proline (105 mg / 100 mL) + Sodium acetate (170 mg / 100 mL) + Sodium chloride (29.3 mg / 100 mL) + Threonine (105 mg / 100 mL) + Tryptophan (45 mg / 100 mL) + Tyrosine (10 mg / 100 mL) + Valine (115 mg / 100 mL) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1993-12-31 2015-08-05 Canada 2.5% Travasol Amino Acid Injection Without Electrolytes In 10% Dextrose Quickmix Lysine hydrochloride (195 mg / 100 mL) + Alanine (520 mg / 100 mL) + Arginine (260 mg / 100 mL) + Dextrose, unspecified form (10 g / 100 mL) + Glycine (520 mg / 100 mL) + Histidine (110 mg / 100 mL) + Isoleucine (120 mg / 100 mL) + L-Leucine hydrochloride (155 mg / 100 mL) + Methionine (195 mg / 100 mL) + Phenylalanine hydrochloride (155 mg / 100 mL) + Proline (105 mg / 100 mL) + Threonine (105 mg / 100 mL) + Tryptophan (45 mg / 100 mL) + Tyrosine (10 mg / 100 mL) + Valine (115 mg / 100 mL) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1995-12-31 2007-08-02 Canada 2.5%travasol Amino Acid InJ.W.eleC.W.25%dex Lysine hydrochloride (145 mg / 100 mL) + Alanine (520 mg / 100 mL) + Arginine (290 mg / 100 mL) + Dextrose, unspecified form (25 g / 100 mL) + Dipotassium phosphate (130.5 mg / 100 mL) + Glycine (260 mg / 100 mL) + Histidine (120 mg / 100 mL) + Isoleucine (150 mg / 100 mL) + Leucine (182.5 mg / 100 mL) + Magnesium chloride (25.5 mg / 100 mL) + Methionine (100 mg / 100 mL) + Phenylalanine (140 mg / 100 mL) + Proline (170 mg / 100 mL) + Serine (125 mg / 100 mL) + Sodium acetate (170 mg / 100 mL) + Sodium chloride (29.3 mg / 100 mL) + Threonine (105 mg / 100 mL) + Tryptophan (45 mg / 100 mL) + Tyrosine (10 mg / 100 mL) + Valine (145 mg / 100 mL) Liquid Intravenous Clintec Nutrition Company 1996-07-30 1998-08-13 Canada 2.75% Travas. Amino Acid InJ.W.elecw.25%dex Lysine hydrochloride (159.5 mg / 100 mL) + Alanine (570 mg / 100 mL) + Arginine (316 mg / 100 mL) + Dextrose, unspecified form (25 g / 100 mL) + Dipotassium phosphate (261 mg / 100 mL) + Glycine (283 mg / 100 mL) + Histidine (132 mg / 100 mL) + Isoleucine (165 mg / 100 mL) + Leucine (201 mg / 100 mL) + Magnesium chloride (51 mg / 100 mL) + Methionine (110 mg / 100 mL) + Phenylalanine (154 mg / 100 mL) + Proline (187 mg / 100 mL) + Serine (137.5 mg / 100 mL) + Sodium acetate (215.5 mg / 100 mL) + Sodium chloride (112 mg / 100 mL) + Threonine (115.5 mg / 100 mL) + Tryptophan (49.5 mg / 100 mL) + Tyrosine (11 mg / 100 mL) + Valine (159.5 mg / 100 mL) Liquid Intravenous Clintec Nutrition Company 1996-07-30 1998-08-13 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Clinimix Lysine (2.00 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (75.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + Leucine (2.01 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US 
Clinimix Lysine (2.00 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (100.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + Leucine (2.01 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US Clinimix Lysine (4.93 g/2L) + Alanine (17.60 g/2L) + Arginine (9.78 g/2L) + Calcium chloride dihydrate (0.66 g/2L) + D-glucose monohydrate (300.00 g/2L) + Dipotassium phosphate (5.22 g/2L) + Glycine (8.76 g/2L) + Histidine (4.08 g/2L) + Isoleucine (5.10 g/2L) + Leucine (6.20 g/2L) + Magnesium chloride hexahydrate (1.02 g/2L) + Methionine (3.40 g/2L) + Phenylalanine (4.76 g/2L) + Proline (5.78 g/2L) + Serine (4.25 g/2L) + Sodium acetate trihydrate (5.94 g/2L) + Sodium chloride (1.54 g/2L) + Threonine (3.57 g/2L) + Tryptophan (1.53 g/2L) + Tyrosine (0.34 g/2L) + Valine (4.93 g/2L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US Effervescent Potassium Chloride Lysine hydrochloride (1.5 g/1) + Potassium bicarbonate (0.7 g/1) + Potassium chloride (1.25 g/1) Tablet, effervescent Oral Qualitest 2006-01-06 2021-07-31 US FREAMINE III %10 1000 ML(SETLI) Lysine (0.73 %) + Alanine (0.71 %) + Arginine (0.95 %) + Cysteine (0.016 %) + Glycine (1.4 %) + Histidine (0.28 %) + Isoleucine (0.69 %) + Leucine (0.91 %) + Methionine (0.53 %) + Phenylalanine (0.56 %) + Proline (1.12 %) + Serine (0.59 %) + Threonine (0.4 %) + Tryptophan (0.15 %) + Valine (0.66 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2013-01-29 2024-01-23 Turkey 
Categories
- ATC Codes
- V03AF11 — Arginine and lysine
- V03AF — Detoxifying agents for antineoplastic treatment
- V03A — ALL OTHER THERAPEUTIC PRODUCTS
- V03 — ALL OTHER THERAPEUTIC PRODUCTS
- V — VARIOUS
- Drug Categories
- Amino Acids
- Amino Acids, Basic
- Amino Acids, Diamino
- Amino Acids, Essential
- Amino Acids, Peptides, and Proteins
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Detoxifying Agents for Antineoplastic Treatment
- Dietary Supplements
- I.V. Solution Additives
- Lysine
- Proteinogenic Amino Acids
- Supplements
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- L-alpha-amino acids
- Alternative Parents
- Medium-chain fatty acids / Amino fatty acids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Amine / Amino acid / Amino fatty acid / Carbonyl group / Carboxylic acid / Fatty acid / Fatty acyl / Hydrocarbon derivative / L-alpha-amino acid
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- lysine, aspartate family amino acid, proteinogenic amino acid, L-alpha-amino acid (CHEBI:18019) / Common amino acids (C00047)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- K3Z4F929H6
- CAS number
- 56-87-1
- InChI Key
- KDXKERNSBIXSRK-YFKPBYRVSA-N
- InChI
- InChI=1S/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1
- IUPAC Name
- (2S)-2,6-diaminohexanoic acid
- SMILES
- NCCCC[C@H](N)C(O)=O
References
- Synthesis Reference
Joseph Michael Stevens, Thomas P. Binder, "Process for making granular L-lysine." U.S. Patent US5990350, issued 0000.
US5990350- General References
- Griffith RS, Norins AL, Kagan C: A multicentered study of lysine therapy in Herpes simplex infection. Dermatologica. 1978;156(5):257-67. [Article]
- External Links
- Human Metabolome Database
- HMDB0000182
- KEGG Drug
- D02304
- KEGG Compound
- C00047
- PubChem Compound
- 5962
- PubChem Substance
- 46504770
- ChemSpider
- 5747
- BindingDB
- 217367
- 6536
- ChEBI
- 18019
- ChEMBL
- CHEMBL8085
- ZINC
- ZINC000001532522
- PharmGKB
- PA450280
- PDBe Ligand
- LYS
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Lysine
- MSDS
- Download (73.3 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Critically Ill Patients / Starvation 1 4 Completed Other Gastroenteropancreatic Neuroendocrine Tumors 1 4 Completed Treatment Diabetic Nephropathy 1 4 Recruiting Basic Science Healthy Subjects (HS) / Obesity / Type 2 Diabetes Mellitus 1 4 Recruiting Prevention Intestinal Obstruction / Ischemia, Mesenteric / Laparotomy 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Basic Organics
- CVS Pharmacy
- Gilead Sciences Inc.
- Longs Drug Store
- Lundbeck Inc.
- Marlex Pharmaceuticals
- Medisca Inc.
- Rite Aid Corp.
- Rugby Laboratories
- Walgreen Co.
- Dosage Forms
Form Route Strength Tablet Oral Tablet, coated Oral Solution Intravenous 10.50 g/1000ml Injection Intravenous 0.5 g/l Injection Intravenous 0.25 g/1000ml Solution, concentrate Intravenous Injection, solution Intravenous Injection Intravenous 11.000 g/1000ml Solution Intravenous 18.5 g/L Injection Intravenous 5.5 g/1000ml Drug delivery system Oral 0.105 g Tablet, chewable Oral Injection, emulsion Intravenous Syrup Oral Tablet, effervescent Oral Emulsion Intravenous 0.468 g Injection Intravenous 16 g/1000ml Tablet Oral 1000 mg Emulsion Parenteral 20.000 g Injection Intravenous 1.6 g/l Solution Parenteral Injection, solution, concentrate Intravenous Injection, emulsion Parenteral Emulsion Intravenous 0.466 g Injection, emulsion; injection, solution Intravenous Emulsion Parenteral Emulsion Intravenous Injection, solution Injection, emulsion Intravenous 4.656 g/1000ml Injection, emulsion Intravenous 6.792 g/1000ml Solution Intraperitoneal Injection, solution Intraperitoneal Liquid Hemodialysis Solution Intraperitoneal 0.184 g/l Liquid Oral Emulsion Intravenous 176 g/l Emulsion Intravenous 4 g Emulsion Intravenous 3 g Solution Intravenous Tablet Oral 105.000 mg Injection Intravenous 4 g/l Injection Intravenous 0.21 g/100ml Liquid Intravenous Emulsion Intravenous 13.000 g Emulsion Parenteral 42.00 g Injection, emulsion Intravenous 14 g/1000ml Tablet Oral 67.000 mg Injection Intravenous 10.30 g/l Injection Intravenous Capsule, gelatin coated Oral Capsule Oral - Prices
Unit description Cost Unit Neoprofen 20 mg/2 ml vial 304.5USD ml Cayston 75 mg inhal solution 63.24USD ml L-lysine ointment 0.16USD g Lysine hcl powder 0.16USD g Ra l-lysine 1000 mg tablet 0.08USD tablet L-lysine hcl 500 mg tablet 0.07USD tablet L-lysine 1000 mg tablet 0.04USD tablet L-lysine 500 mg tablet 0.04USD tablet CVS Pharmacy l-lysine 500 mg tablet 0.03USD tablet Lysine 500 mg tablet 0.02USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 224.5 dec °C PhysProp water solubility 1E+006 mg/L (at 20 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP -3.05 HANSCH,C ET AL. (1995) pKa 3.12 (at 0 °C) KORTUM,G ET AL (1961) - Predicted Properties
Property Value Source Water Solubility 105.0 mg/mL ALOGPS logP -3.8 ALOGPS logP -3.2 Chemaxon logS -0.14 ALOGPS pKa (Strongest Acidic) 2.74 Chemaxon pKa (Strongest Basic) 10.29 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 89.34 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 37.81 m3·mol-1 Chemaxon Polarizability 15.84 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Download (9.31 KB)
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 136.8279732 predictedDarkChem Lite v0.1.0 [M-H]- 136.9242732 predictedDarkChem Lite v0.1.0 [M-H]- 136.8383732 predictedDarkChem Lite v0.1.0 [M-H]- 136.7398732 predictedDarkChem Lite v0.1.0 [M-H]- 136.9309732 predictedDarkChem Lite v0.1.0 [M-H]- 128.05656 predictedDeepCCS 1.0 (2019) [M+H]+ 137.4808732 predictedDarkChem Lite v0.1.0 [M+H]+ 137.3650732 predictedDarkChem Lite v0.1.0 [M+H]+ 128.9883606 predictedDarkChem Standard v0.1.0 [M+H]+ 137.2940732 predictedDarkChem Lite v0.1.0 [M+H]+ 137.5583732 predictedDarkChem Lite v0.1.0 [M+H]+ 131.35274 predictedDeepCCS 1.0 (2019) [M+Na]+ 137.0372732 predictedDarkChem Lite v0.1.0 [M+Na]+ 136.8191732 predictedDarkChem Lite v0.1.0 [M+Na]+ 137.0022732 predictedDarkChem Lite v0.1.0 [M+Na]+ 136.8410732 predictedDarkChem Lite v0.1.0 [M+Na]+ 137.0409732 predictedDarkChem Lite v0.1.0 [M+Na]+ 140.0974 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- L-ornithine transmembrane transporter activity
- Specific Function
- High-affinity, low capacity permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine) in non-hepatic tissues. May also function as an ecotropic retroviral leuk...
- Gene Name
- SLC7A1
- Uniprot ID
- P30825
- Uniprot Name
- High affinity cationic amino acid transporter 1
- Molecular Weight
- 67637.62 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Fernandez J, Lopez AB, Wang C, Mishra R, Zhou L, Yaman I, Snider MD, Hatzoglou M: Transcriptional control of the arginine/lysine transporter, cat-1, by physiological stress. J Biol Chem. 2003 Dec 12;278(50):50000-9. Epub 2003 Sep 30. [Article]
- Lopez AB, Wang C, Huang CC, Yaman I, Li Y, Chakravarty K, Johnson PF, Chiang CM, Snider MD, Wek RC, Hatzoglou M: A feedback transcriptional mechanism controls the level of the arginine/lysine transporter cat-1 during amino acid starvation. Biochem J. 2007 Feb 15;402(1):163-73. [Article]
- Nicholson B, Sawamura T, Masaki T, MacLeod CL: Increased Cat3-mediated cationic amino acid transport functionally compensates in Cat1 knockout cell lines. J Biol Chem. 1998 Jun 12;273(24):14663-6. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- L-ornithine transmembrane transporter activity
- Specific Function
- Involved in the transport of the cationic amino acids (arginine, lysine and ornithine).
- Gene Name
- SLC7A4
- Uniprot ID
- O43246
- Uniprot Name
- Cationic amino acid transporter 4
- Molecular Weight
- 68267.17 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Rotoli BM, Bussolati O, Sala R, Gazzola GC, Dall'Asta V: The transport of cationic amino acids in human airway cells: expression of system y+L activity and transepithelial delivery of NOS inhibitors. FASEB J. 2005 May;19(7):810-2. Epub 2005 Mar 3. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- L-ornithine transmembrane transporter activity
- Specific Function
- Mediates the uptake of the cationic amino acids arginine, lysine and ornithine in a sodium-independent manner.
- Gene Name
- SLC7A3
- Uniprot ID
- Q8WY07
- Uniprot Name
- Cationic amino acid transporter 3
- Molecular Weight
- 67168.31 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Hosokawa H, Sawamura T, Kobayashi S, Ninomiya H, Miwa S, Masaki T: Cloning and characterization of a brain-specific cationic amino acid transporter. J Biol Chem. 1997 Mar 28;272(13):8717-22. [Article]
- Humphrey BD, Stephensen CB, Calvert CC, Klasing KC: Lysine deficiency and feed restriction independently alter cationic amino acid transporter expression in chickens (Gallus gallus domesticus). Comp Biochem Physiol A Mol Integr Physiol. 2006 Feb;143(2):218-27. Epub 2006 Jan 10. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Low-affinity l-arginine transmembrane transporter activity
- Specific Function
- Functions as permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine); the affinity for its substrates differs between isoforms created by alternative splicin...
- Gene Name
- SLC7A2
- Uniprot ID
- P52569
- Uniprot Name
- Cationic amino acid transporter 2
- Molecular Weight
- 71672.175 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Low BC, Grigor MR: Angiotensin II stimulates system y+ and cationic amino acid transporter gene expression in cultured vascular smooth muscle cells. J Biol Chem. 1995 Nov 17;270(46):27577-83. [Article]
- Rotoli BM, Bussolati O, Sala R, Gazzola GC, Dall'Asta V: The transport of cationic amino acids in human airway cells: expression of system y+L activity and transepithelial delivery of NOS inhibitors. FASEB J. 2005 May;19(7):810-2. Epub 2005 Mar 3. [Article]
- Schwartz D, Schwartz IF, Gnessin E, Wollman Y, Chernichovsky T, Blum M, Iaina A: Differential regulation of glomerular arginine transporters (CAT-1 and CAT-2) in lipopolysaccharide-treated rats. Am J Physiol Renal Physiol. 2003 Apr;284(4):F788-95. Epub 2002 Dec 10. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Trna binding
- Specific Function
- Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of...
- Gene Name
- KARS
- Uniprot ID
- Q15046
- Uniprot Name
- Lysine--tRNA ligase
- Molecular Weight
- 68047.54 Da
References
- Wu XR, Kenzior A, Willmot D, Scanlon S, Chen Z, Topin A, He SH, Acevedo A, Folk WR: Altered expression of plant lysyl tRNA synthetase promotes tRNA misacylation and translational recoding of lysine. Plant J. 2007 May;50(4):627-36. Epub 2007 Apr 8. [Article]
- Chou TF, Wagner CR: Lysyl-tRNA synthetase-generated lysyl-adenylate is a substrate for histidine triad nucleotide binding proteins. J Biol Chem. 2007 Feb 16;282(7):4719-27. Epub 2006 Dec 8. [Article]
- Kamenski P, Kolesnikova O, Jubenot V, Entelis N, Krasheninnikov IA, Martin RP, Tarassov I: Evidence for an adaptation mechanism of mitochondrial translation via tRNA import from the cytosol. Mol Cell. 2007 Jun 8;26(5):625-37. [Article]
- Kwon I, Wang P, Tirrell DA: Design of a bacterial host for site-specific incorporation of p-bromophenylalanine into recombinant proteins. J Am Chem Soc. 2006 Sep 13;128(36):11778-83. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Transporter activity
- Specific Function
- Sodium-independent transporter that mediates the update of aromatic acid. Can function as a net efflux pathway for aromatic amino acids in the basosolateral epithelial cells (By similarity).
- Gene Name
- SLC16A10
- Uniprot ID
- Q8TF71
- Uniprot Name
- Monocarboxylate transporter 10
- Molecular Weight
- 55492.07 Da
References
- Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H: Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. J Biol Chem. 2001 May 18;276(20):17221-8. Epub 2001 Feb 20. [Article]
- Kim DK, Kanai Y, Matsuo H, Kim JY, Chairoungdua A, Kobayashi Y, Enomoto A, Cha SH, Goya T, Endou H: The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location. Genomics. 2002 Jan;79(1):95-103. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Symporter activity
- Specific Function
- Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
- Gene Name
- SLC22A4
- Uniprot ID
- Q9H015
- Uniprot Name
- Solute carrier family 22 member 4
- Molecular Weight
- 62154.48 Da
References
- Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [Article]
Drug created at June 13, 2005 13:24 / Updated at January 02, 2024 23:42